| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5597164 | The Annals of Thoracic Surgery | 2016 | 8 Pages |
Abstract
LCNEC showed overexpression of topoisomerase II, somatostatin, and ERCC1. These findings suggested that it was possible to have good response to treatment with etoposide and octreotide and that LCNEC may be resistant to platinum-based therapy compared with adenocarcinoma. EGFR mutations were not observed in LCNEC. These results may indicate a favorable response to adjuvant treatments that are not typically prescribed for non-small cell lung cancer.
Keywords
topoisomerase-IITUBB3SSTclass III β-tubulinSSTRTKILCNECEGFRAdenocarcinomaoverall survivalSCLCexcision repair cross-complementation group 1NSCLCSomatostatinTyrosine kinase inhibitorERCC1non-small cell lung carcinomaSmall cell lung carcinomaLarge cell neuroendocrine carcinomaSomatostatin receptorEpidermal growth factor receptor
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Takashi MD, Tetuo MD, PhD, Yoshinobu MD, PhD, Hajime MD, PhD, Satoshi MD, Kazutoshi MD, PhD, Naobumi MD, PhD, Kazutoshi MD, PhD, Sakae MD, PhD, Akira MD, PhD,